MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus.

Autor: DeBarros K; Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA., Khan M; Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA., Coleman M; Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA., Bond VC; Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA., Floyd V; Department of Community Health and Preventive Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA., Gbodossou E; PROMETRA International, Dakar-Etoile BP 6134, Senegal., Diop A; Malango Traditional Healers Association, Fatick BP 1763, Senegal., Krumpe LRH; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA., O'Keefe BR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.; Natural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, USA., Powell MD; Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310, USA.

Publikováno v: Viruses [Viruses] 2024 Sep 07; Vol. 16 (9). Date of Electronic Publication: 2024 Sep 07.

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2.

Autor: Muñoz-Basagoiti J; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain., Monteiro FLL; Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Krumpe LRH; Molecular Targets Program, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, MD 21702.; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702., Armario-Najera V; Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain., Shenoy SR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, MD 21702.; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702., Perez-Zsolt D; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain., Westgarth HJ; Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Villorbina G; Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain., Bomfim LM; Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Raïch-Regué D; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain., Nogueras L; Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain., Henrich CJ; Molecular Targets Program, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, MD 21702.; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702., Gallemí M; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain., Moreira FRR; Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Torres P; Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain., Wilson J; Molecular Targets Program, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, MD 21702.; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702., D'arc M; Laboratory of Diversity and Viral Diseases, Institute of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Marfil S; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain., Herlinger AL; Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Pradenas E; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain., Higa LM; Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Portero-Otin M; Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain., Trinité B; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain., Twyman RM; Twyman Research Management Ltd, Scarborough YO11 9FJ, UK., Capell T; Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain., Tanuri A; Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil., Blanco J; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain.; Germans Trias i Pujol Research Institute, Badalona 08916, Spain.; Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Madrid 28029, Spain.; Universitat de Vic - Universitat Central de Catalunya, Vic 08500, Spain., Izquierdo-Useros N; IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain.; Germans Trias i Pujol Research Institute, Badalona 08916, Spain.; Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Madrid 28029, Spain., Rech EL; Embrapa Genetic Resources and Biotechnology National Institute of Science and Technology in Synthetic Biology, Brasília 70770-917, Brazil., Christou P; Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain.; ICREA, Catalan Institute for Research and Advanced Studies, Barcelona 08010, Spain., O'Keefe BR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, MD 21702.; Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2023 Mar 07; Vol. 120 (10), pp. e2214561120. Date of Electronic Publication: 2023 Feb 28.

Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I.

Autor: Krumpe LRH; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Wilson BAP; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Marchand C; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, NCI, NIH, Bethesda, Maryland 20892, United States., Sunassee SN; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Bermingham A; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Wang W; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, NCI, NIH, Bethesda, Maryland 20892, United States., Price E; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Guszczynski T; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Kelley JA; Chemical Biology Laboratory, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Gustafson KR; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States., Pommier Y; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, NCI, NIH, Bethesda, Maryland 20892, United States., Rosengren KJ; School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia., Schroeder CI; Chemical Biology Laboratory, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States.; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia., O'Keefe BR; Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States.; Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702, United States.

Publikováno v: Journal of the American Chemical Society [J Am Chem Soc] 2020 Dec 16; Vol. 142 (50), pp. 21178-21188. Date of Electronic Publication: 2020 Dec 02.

The Natural Product Butylcycloheptyl Prodiginine Binds Pre-miR-21, Inhibits Dicer-Mediated Processing of Pre-miR-21, and Blocks Cellular Proliferation.

Autor: Matarlo JS; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA., Krumpe LRH; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Heinz WF; Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Oh D; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA., Shenoy SR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Thomas CL; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA., Goncharova EI; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA; Biomedical Informatics and Data Science Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Lockett SJ; Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., O'Keefe BR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA; Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA. Electronic address: okeefeba@mail.nih.gov.

Publikováno v: Cell chemical biology [Cell Chem Biol] 2019 Aug 15; Vol. 26 (8), pp. 1133-1142.e4. Date of Electronic Publication: 2019 May 30.

Gene-silencing suppressors for high-level production of the HIV-1 entry inhibitor griffithsin in Nicotiana benthamiana .

Autor: Habibi P; Department of Bioprocess Engineering and Biotechnology, Federal University of Paraná, Curitiba, PR, Brazil.; Embrapa Genetic Resources and Biotechnology, PqEB-Final W5 Norte - CP 02372, Brasília-DF, Brazil., Soccol CR; Department of Bioprocess Engineering and Biotechnology, Federal University of Paraná, Curitiba, PR, Brazil., O'Keefe BR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA.; Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, USA., Krumpe LRH; Basic Science Program, Leidos Biomedical Research, Inc., Molecular Targets Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wilson J; Molecular Targets Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA., de Macedo LLP; Embrapa Genetic Resources and Biotechnology, PqEB-Final W5 Norte - CP 02372, Brasília-DF, Brazil., Faheem M; Embrapa Genetic Resources and Biotechnology, PqEB-Final W5 Norte - CP 02372, Brasília-DF, Brazil., Dos Santos VO; Embrapa Genetic Resources and Biotechnology, PqEB-Final W5 Norte - CP 02372, Brasília-DF, Brazil., Prado GS; Embrapa Genetic Resources and Biotechnology, PqEB-Final W5 Norte - CP 02372, Brasília-DF, Brazil., Botelho MA; Post Graduation Program in Biotechnology, University Potiguar, Natal, RN, Brazil., Lacombe S; IRD, CIRAD, Universite Montpellier, Interactions Plantes Microorganismes et Environnement (IPME), Montpellier, France., Grossi-de-Sa MF; Embrapa Genetic Resources and Biotechnology, PqEB-Final W5 Norte - CP 02372, Brasília-DF, Brazil.; Catholic University of Brasília, Brasília-DF, Brazil.; Post Graduation Program in Biotechnology, University Potiguar, Natal, RN, Brazil.

Publikováno v: Process biochemistry (Barking, London, England) [Process Biochem] 2018 Jul; Vol. 70, pp. 45-54. Date of Electronic Publication: 2018 Apr 10.